of raw materials from abroad was done through the purchase department of Merck Darmstard and, (c) that 80 per cent to 90 per cent of items marketed as Laboratory Chemicals by Merck India are repacked straight either from imported or indigenous raw materials.

The matter was taken up with the corn-par, y who has clarified that more than 40 qualified chemists are working on Laboratory Chemicals. The company has denied the allegation that they are merely repacking the imported or indigenous raw materials and stated that their activities involve highly sophisticated technology and conforms to the industrial licence issued to them for laboratory chemicals and re-agents. The company has also clarified that the purchase of raw materials is not made through the purchase department of M/s. Merck Darmstard (the for-eign collaboration) and that they have their own purchase department through which they organise all purchases. The company has further clarified that in terms of licence for laboratory chemicals granted to them, no unfair business practices is being adopted.

Show cause notice for marketing products without price approval

2192. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention wa$_s$ drawn to the news item captioned 'show cause no tices to 2 drug companies' which appeared in the 'Financial Express' of 21st Novem ber, 1985;

(b) whether it is $_a$ fact that Government have issued nonces *to* drug companies who are marketing their products without obtaining price approval;

(c) if so, names of the companies and when it came to the notice of Government that each of thos$_e$ companies have crossed the exempted limit of sales turn over of Rupees Fifty lacs per annum;

(d) whether it is also a fact that there are number of drug companies who are marketing their products without price approval even when the sales turn over of each of 'heir predicts has crossed Rupees one crore; and

(e) if $_s$o, names of such products and their manufacturers?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAI-CHANDRA SINGH); (a) Yes, Sir.

(b) to (e) A large number of notices have been issued to the drug manufacturing companies for *prima facie* not obtaining price approval even after crossing the limit of Rs. 50 lakhs in sales turnover. Names of such companies were given in reply to Rajya Sabha Unstarred Question No. 1557 answered on 2nd December, 1985. Names of the products of such companies having sales turnover of Rs. 1 crore or more $^{nave\ not}$ been identified a$_s$ the sales turnover of formulations is not monitored.

Show cause notices to drug manufacturers

2193. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to the Unstarred Question 188 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) when were the show cause notices issued to Burroughs Wellcome, Pfizer and Glaxo and when were the explanation of each company received;

(b) what were the main grounds on which each show cause notice was issued;

(c) what are the bulk drugs involved in each case and what is the permitted capacity of each company as well as what was the production of each company during the last three years; year-wise;

(d) whether it is a fact that these companies did not implemented the prices fixed by Government for those drugs and have been charging their own prices up-till today;

(e) whether it is also a fact that over charging is the main consideration of these companies for unauthorised excess pro-